Inadequate Warnings Expand Onglyza MDL
Inadequate Warnings Expand Onglyza MDL
Introduction
A growing number of Onglyza lawsuits are fast becoming a part of MDL No. 2809 established in February for coordinated pretrial proceedings. AstraZeneca and Bristol Myers Squibb are the defendants named in this litigation. Cases have been coordinated in the U.S. District Court for the Eastern District of Kentucky under District Judge Karen K. Caldwell.
Recently, a lawsuit was filed in the U.S. District Court for the Eastern District of Kentucky by a plaintiff, who claims that the use of Onglyza and Kombiglyze XR led to the development of his heart failure and other related injuries, which could have been avoided if the drug makers had provided adequate warnings. His claim also details how the defendants continued to market Onglyza and Kombiglyze XR as safe and effective, in spite of being well aware of the heart failure risks.
Comments
Latest News
Walgreens Settles Federal Opioid Case for $300 Million
Categories: Opioids
Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.
The U.S. Department of Justice announced on Monday…
Study: Opioid Use in Pregnancy May Shrink Newborn Brains
Categories: Opioids
New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…
Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting
Categories: Opioids
The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…